Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltanexor with Inqovi in High-Risk Myelodysplastic Syndromes
NCT05918055Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eltanexor in myelodysplastic syndrome (MDS) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 28 days, Dose-limiting Toxicity at 28 days and 1 more. Started Nov 2023; status: terminated.
02
Drugs
eltanexor
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05918055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918055.